Exclusive Summary

• **Demonstrable Best-in-Class Potential**: Head-to-head clinical data indicates UB346 (Tazovid) achieves faster viral clearance (8.4 days) and superior antiviral potency (7-10x better IC50) compared to Pfizer's Paxlovid, specifically effective against key variants like XBB.
• **Significant Cost & Dosage Advantage**: With a daily dosage of only 300mg (half that of Paxlovid), UB346 offers lower API manufacturing costs and pricing flexibility, making it highly attractive for price-sensitive emerging markets.
• **Global Validation & Expansion Potential**: Backed by the ongoing Oxford University-led PLATCOV trial for international credibility, the asset also offers lucrative lifecycle management opportunities in veterinary medicine (FIP) and other viral indications.

资产材料

联系我们获取完整材料